Amedisys Stock Analysis


USD 88.41  2.57  2.82%   

The latest dip in stock price could raise concerns from shareholders as the firm is trading at a share price of 88.41 on 316,092 in volume. The company directors and management have failed to build on market volatilities in November. However, diversifying your overall positions with Amedisys may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.03. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Amedisys partners.
Please continue to Trending Equities.
The Amedisys stock analysis report makes it easy to digest most publicly released information about Amedisys and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Amedisys Stock analysis module also helps to analyze the Amedisys price relationship with some important fundamental indicators such as market cap and management efficiency.

Amedisys Stock Analysis Notes

About 98.0% of the company shares are held by institutions such as insurance companies. The book value of Amedisys was presently reported as 31.27. The company has Price/Earnings To Growth (PEG) ratio of 1.13. Amedisys had not issued any dividends in recent years. The entity had 4:3 split on the 5th of December 2006. Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana. Amedisys operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange. It employs 21000 people. For more info on Amedisys please contact Paul Kusserow at 225 292 2031 or go to

Amedisys Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Amedisys' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Amedisys or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Amedisys generated a negative expected return over the last 90 days
Amedisys has high historical volatility and very poor performance
Amedisys has a strong financial position based on the latest SEC filings
Over 98.0% of the company shares are held by institutions such as insurance companies
Latest headline from How the Hospice Movement Became a For-Profit Hustle ProPublica - ProPublica

Amedisys Upcoming and Recent Events

Earnings reports are used by Amedisys to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Amedisys previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report23rd of February 2022
Next Financial Report27th of April 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Amedisys Largest EPS Surprises

Earnings surprises can significantly impact Amedisys' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Amedisys SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Amedisys prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Amedisys investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Amedisys specific information freely available to individual and institutional investors to make a timely investment decision.
2nd of August 2022
Financial Statements and Exhibits. Regulation FD Disclosure
27th of July 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
24th of June 2022
Financial Statements and Exhibits. Regulation FD Disclosure
13th of June 2022
Submission of Matters to a Vote of Security Holders
9th of June 2022
Financial Statements and Exhibits. Regulation FD Disclosure
6th of June 2022
Financial Statements and Exhibits. Regulation FD Disclosure
27th of April 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
4th of April 2022
Financial Statements and Exhibits. Regulation FD Disclosure

Amedisys Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.96 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Amedisys's market, we take the total number of its shares issued and multiply it by Amedisys's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Amedisys Profitablity

Amedisys' profitability indicators refer to fundamental financial ratios that showcase Amedisys' ability to generate income relative to its revenue or operating costs. If, let's say, Amedisys is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Amedisys' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Amedisys' profitability requires more research than a typical breakdown of Amedisys' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.05 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.09 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.0.
Last ReportedProjected for 2022
Return on Investment 20.99  22.65 
Return on Average Assets 12.21  13.17 
Return on Average Equity 24.02  25.92 
Return on Invested Capital 0.58  0.63 
Return on Sales 0.13  0.14 

Management Efficiency

The entity has return on total asset (ROA) of 0.0656 % which means that it generated profit of $0.0656 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.1191 %, meaning that it created $0.1191 on every $100 dollars invested by stockholders. Amedisys management efficiency ratios could be used to measure how well amedisys manages its routine affairs as well as how well it operates its assets and liabilities. The current year Return on Investment is expected to grow to 22.65. The current year Return on Average Assets is expected to grow to 13.17. Amedisys Goodwill and Intangible Assets are projected to increase significantly based on the last few years of reporting. The past year's Goodwill and Intangible Assets were at 1.31 Billion. The current year Tax Assets is expected to grow to about 296.6 K, whereas Assets Non Current are forecasted to decline to about 1.2 B.
Last ReportedProjected for 2022
Book Value per Share 28.53  24.86 
Enterprise Value over EBIT 20.00  28.00 
Enterprise Value over EBITDA 15.83  17.89 
Price to Book Value 5.67  5.54 
Tangible Assets Book Value per Share 16.84  17.24 
Enterprise Value5.7 B4.7 B
Tangible Asset Value549.7 M556.4 M

Technical Drivers

As of the 2nd of December, Amedisys shows the mean deviation of 2.21, and Risk Adjusted Performance of (0.18). Amedisys technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Amedisys, which can be compared to its rivals. Please confirm Amedisys downside deviation, treynor ratio, expected short fall, as well as the relationship between the variance and potential upside to decide if Amedisys is priced correctly, providing market reflects its regular price of 88.41 per share. Given that Amedisys has jensen alpha of (0.50), we suggest you to validate Amedisys's prevailing market performance to make sure the company can sustain itself at a future point.

Amedisys Price Movement Analysis

The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Triangular Moving Average shows Amedisys double smoothed mean price over a specified number of previous prices (i.e., averaged twice).

Amedisys Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amedisys insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amedisys' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Amedisys insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Amedisys Technical and Predictive Indicators

Amedisys Forecast Models

Amedisys time-series forecasting models is one of many Amedisys' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Amedisys' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Amedisys Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Amedisys prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Amedisys shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Amedisys. By using and applying Amedisys Stock analysis, traders can create a robust methodology for identifying Amedisys entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin 11.31  12.21 
EBITDA Margin 13.33  14.38 
Gross Margin 44.63  48.66 
Profit Margin 9.39  10.13 

Current Amedisys Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Amedisys analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Amedisys analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Amedisys current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Amedisys analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Amedisys stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Amedisys, talking to its executives and customers, or listening to Amedisys conference calls.
Amedisys Analyst Advice Details

Amedisys Stock Analysis Indicators

Amedisys stock analysis indicators help investors evaluate how Amedisys stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Amedisys shares will generate the highest return on investment. By understating and applying Amedisys stock analysis, traders can identify Amedisys position entry and exit signals to maximize returns.
Begin Period Cash Flow83357000.00
Logo U R LimglogosUSAMED.png
Common Stock Shares Outstanding33268000.00
Total Stockholder Equity931351000.00
DescriptionAmedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments Home Health, Hospice, Personal Care, and High Acuity Care. T
Total Cashflows From Investing Activities-281607000.00
Tax Provision70065000.00
Quarterly Earnings Growth Y O Y-0.424
Property Plant And Equipment Net119692000.00
Retained Earnings639063000.00
Cash And Short Term Investments42694000.00
Retained Earnings Total Equity639063000.00
Accounts Payable38217000.00
Net Debt502918000.00
50 Day M A94.524
Total Current Liabilities374282000.00
Currency CodeUSD
Other Operating Expenses1962197000.00
Non Current Assets Total1500284000.00
Forward Price Earnings16.8634
Common Stock Total Equity38000.00
Non Currrent Assets Other73023000.00
Please continue to Trending Equities. Note that the Amedisys information on this page should be used as a complementary analysis to other Amedisys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Amedisys Stock analysis

When running Amedisys price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Is Amedisys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine Amedisys value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.